ArticlePloS one2021

Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.

Riichiro Suenaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.